Methods	Randomised controlled trial
Participants	85 FIGO (1976) IA-IB Grade 2 and 3
Interventions	Cisplatin 50 mg/m2 × 6 cycles Q 28/7 versus observation
Outcomes	DFS 83% versus 64% OS 88% versus 82% Adverse events in adjuvant chemotherapy arm: nausea and vomiting in more than 2/3 of patients; but in severe form in less than 10% of courses; leukopenia and thrombocytopenia in 14% of patients but >= Grade 3 in only 1% of patients; no episodes of febrile infection Adverse events in no adjuvant chemotherapy arm: not reported Median follow-up: 69 months
Notes	Patients with residual disease in both arms
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Based on tables of random numbers
Allocation concealment (selection bias)	Low risk	Central randomisation by telephone call to co-ordinating centre
Incomplete outcome data (attrition bias) All outcomes	Low risk	Deemed ineligible after randomisation: T: 0/41 (0%) C: 2/44 (5%) Did not report whether any further loss to follow-up occurred
Blinding of outcome assessors (detection bias)	Unclear risk	Not reported
Selective reporting (reporting bias)	Unclear risk	Intention-to-treat analysis; adverse events in the ‘no adjuvant chemotherapy’ arm were not reported